On this page
The current hyperthyroidism schedule is a timed rating, not a permanent symptom ladder. Under 38 CFR § 4.119 (opens in a new tab), DC 7900 assigns 30 percent for six months after the initial diagnosis. Thereafter, VA rates the remaining disease or complications of treatment under the appropriate body-system codes.
That makes follow-up evidence critical. Graves' eye disease, atrial fibrillation, other hyperthyroid heart disease, and hypothyroidism after radioiodine or surgery can outlast the initial six-month period. If those residuals are not identified, the record may show only that the temporary DC 7900 period ended.
TL;DR
- Hyperthyroidism, including Graves' disease, is DC 7900.
- DC 7900 provides 30 percent for six months after the initial diagnosis.
- After six months, VA rates residual disease and treatment complications under the affected body systems.
- Hyperthyroid cardiovascular or cardiac disease is evaluated separately under DC 7008.
- Graves' eye involvement is evaluated separately under the applicable diplopia, visual-acuity, or other eye code.
- Treatment may cause hypothyroidism, which follows DC 7903 rather than continuing the temporary DC 7900 percentage.
- Endocrinopathies appear on the chronic-disease list in 38 CFR § 3.309(a) (opens in a new tab); the one-year presumption has service-length and manifestation requirements.
- Across 447 decided Board rulings on hyperthyroidism from 2021 to 2026, 19.7% were granted, 27.1% denied and 53.2% remanded.
Hyperthyroidism VA rating criteria (DC 7900)
Since December 10, 2017, when VA's revised endocrine schedule took effect (82 FR 50802), DC 7900 has read as follows.
7900 Hyperthyroidism, including, but not limited to, Graves' disease:
| Rating | Criteria |
|---|---|
| 30% | For six months after initial diagnosis |
| Thereafter, rate residuals of disease or complications of medical treatment within the appropriate diagnostic code(s) within the appropriate body system. |
Note (1): If hyperthyroid cardiovascular or cardiac disease is present, separately evaluate under DC 7008 (hyperthyroid heart disease).
Note (2): Separately evaluate eye involvement occurring as a manifestation of Graves' Disease as diplopia (DC 6090); impairment of central visual acuity (DCs 6061-6066); or under the most appropriate DCs in § 4.79.
At the 2026 rates, 30 percent pays $552.47 a month for a veteran with no dependents.
The date matters. The 30 percent covers the six months after the initial diagnosis, not the six months after you file. In two 2025 decisions, the Board denied a compensable rating because the veteran was diagnosed years before the effective date of service connection, so the temporary period fell outside the appeal, and no ratable residuals were shown (A25001152, A25002225). Submit the initial diagnostic record, thyroid laboratory results, and treatment timeline so VA can place the six-month period accurately.
Older articles may show a 10, 30, 60 and 100 percent ladder based on tachycardia, tremor, weight loss, and other findings. That old symptom ladder is not the current DC 7900 schedule. It still matters for a claim pending before December 10, 2017: the Board weighs both versions and applies the more favorable one, using the new criteria only from that date (25002361). Otherwise those symptoms matter as evidence of residual disability, not as a percentage table.
Hyperthyroidism residuals after six months
Hyperthyroid heart disease (DC 7008)
DC 7008 has no percentages of its own. It says to "Rate under the appropriate cardiovascular diagnostic code, depending on particular findings." Atrial fibrillation, a recognized complication of hyperthyroidism, is listed as a supraventricular tachycardia under DC 7010, so the heart arrhythmia page explains its levels. The record may need cardiology diagnoses, ECG or monitor results, METs testing when applicable, medication history, and an opinion connecting the heart condition to hyperthyroidism. Palpitations alone do not identify the diagnosis.
Graves' eye disease
Note (2) sends eye involvement from Graves' disease to the eye codes: diplopia, central visual acuity, or the most appropriate code in § 4.79. Thyroid eye disease can cause eyelid retraction, swelling, bulging eyes and double vision. It does not always resolve on its own, and a small share of people have it while their thyroid levels are normal. Ophthalmology records should distinguish thyroid eye disease from dry eye, refractive error, and unrelated eye conditions.
Hypothyroidism after treatment
Radioactive iodine or thyroidectomy can leave you hypothyroid; in one study of Graves' disease patients treated with radioactive iodine, most of those cured became hypothyroid within six months. That residual follows hypothyroidism and DC 7903, which is also time-limited: its 30 percent level for hypothyroidism without myxedema lasts six months after diagnosis before residuals are rated. The record should show that the hypothyroidism resulted from treatment of the service-connected hyperthyroidism so the disease process is not treated as unrelated.
Other residuals
Other residuals are rated under their own body systems when medically attributed to the disease or treatment. In one 2025 decision, the veteran held separate ratings for vitiligo and for constipation associated with hyperthyroidism (25002361). If a toxic goiter caused the hyperthyroidism, DC 7901 sends the hyperthyroid symptoms to DC 7900 and rates any neck disfigurement separately under DC 7800.
Is hyperthyroidism service connected?
Direct service connection
Direct service connection under 38 CFR § 3.303 (opens in a new tab) may be supported by an in-service diagnosis, abnormal thyroid studies, or a documented symptom pattern later explained by the current diagnosis. Hyperthyroidism is confirmed by blood tests, such as a low TSH with high thyroid hormone levels, so a retrospective medical opinion should address the laboratory and clinical record rather than symptoms alone.
One-year chronic-disease presumption
Section 3.309(a) lists endocrinopathies as chronic diseases. Under § 3.307 (opens in a new tab), 90 days or more of service during a war period or after December 31, 1946, and manifestation to a degree of 10 percent or more within one year after separation can support presumptive service connection. A diagnosis years later does not become presumptive merely because hyperthyroidism is an endocrinopathy.
Secondary service connection
Medication, treatment, or another service-connected condition may support a secondary theory under § 3.310 (opens in a new tab). Some hyperthyroidism is caused by drugs such as amiodarone, tyrosine kinase inhibitors and immune checkpoint inhibitors. The opinion has to explain that the service-connected condition or its treatment caused the hyperthyroidism, or aggravated it, meaning it would be less severe but for that condition. Temporal sequence by itself is not a nexus.
Evidence for a hyperthyroidism VA claim
- Initial diagnosis date and thyroid laboratory values.
- Graves' antibodies, imaging, or specialist diagnosis when applicable.
- Medication, radioiodine, and surgery dates.
- Cardiology records for arrhythmia or hyperthyroid heart disease.
- Ophthalmology records for thyroid eye disease.
- Follow-up thyroid studies showing persistent hyperthyroidism or treatment-induced hypothyroidism.
- Work and daily-function evidence tied to the diagnosed residuals.
The Thyroid and Parathyroid DBQ shows what a compensation and pension (C&P) examiner records. Bring the dated treatment timeline, and make sure heart and eye findings are written down, because those residuals carry the rating after six months.
Why VA denies hyperthyroidism claims
Across 447 decided Board rulings on hyperthyroidism from 2021 to 2026, 19.7% were granted, 27.1% denied and 53.2% remanded. A ruling is one issue the Board decided in one decision; one decision often rules on several issues. That grant rate is 5.0 percentage points below the 24.7 percent across all decided Board rulings, and remand is the most common outcome. The Board section below shows why these claims were sent back, how direct and presumptive claims compared, and how results have changed since 1992.
The gaps below are checks for your records, not a statistical ranking of Board denials.
- Applying the old symptom ladder as current law.
- Treating the initial 30 percent as permanent.
- Expecting the 30 percent when the initial diagnosis came long before the effective date of service connection.
- Allowing the temporary rating to end without identifying ratable residuals.
- Claiming palpitations or eye irritation without a diagnosed complication and medical attribution.
- Calling a diagnosis outside the one-year window presumptive without evidence of compensable manifestation during the window.
Questions veterans ask about hyperthyroidism
What is the VA rating for hyperthyroidism?
Hyperthyroidism is rated 30 percent for six months after the initial diagnosis under DC 7900. After that, VA rates what remains, such as heart disease, eye involvement or hypothyroidism after treatment, under those body systems.
How much does VA pay for hyperthyroidism?
At the 2026 rates, the 30 percent rating pays $552.47 a month for a veteran with no dependents while it lasts. After six months, your pay depends on the residual ratings and your combined rating.
Can I get 30 percent if I was diagnosed years before I filed?
Usually not. The 30 percent covers only the six months after the initial diagnosis, and the Board has denied it where that window ended before the effective date of service connection (A25001152, A25002225). Your rating then rests on residuals.
Is hyperthyroidism presumptive for Agent Orange?
No. The Agent Orange list in 38 U.S.C. § 1116 names hypothyroidism, not hyperthyroidism, so you prove hyperthyroidism on a direct, secondary or one-year chronic-disease basis. In one 2025 case, VA corrected a grant that had treated hyperthyroidism as herbicide-presumptive but kept service connection on a medical opinion linking it to the veteran's exposure (A25002225).
Is Graves' disease rated as hyperthyroidism?
Yes. DC 7900 covers "Hyperthyroidism, including, but not limited to, Graves' disease," and eye involvement from Graves' disease is rated separately under the eye codes.
Bottom Line
Hyperthyroidism begins with a simple six-month DC 7900 rule and then becomes a residual-rating problem. Preserve the initial diagnosis date, but build the long-term record around the conditions that remain: heart disease, eye involvement, hypothyroidism after treatment, or other medically established complications.
Methodology and Limitations
- Data source: 38 CFR § 4.119, DCs 7900, 7901 and 7903 (endocrine rule 82 FR 50802, effective December 10, 2017), DCs 7008 and 7010 in § 4.104, the eye codes in § 4.79, 38 CFR §§ 3.303, 3.307, 3.309 and 3.310, and 38 U.S.C. § 1116, checked on October 10, 2026 against the eCFR text current to October 2, 2026. The decision numbers in parentheses are 2025 Board decisions.
- Sample size: Board figures come from Claim Raven's read of 510,968 Board decisions from 2021 to 2026, containing 1,376,193 rulings, including 447 decided Board rulings on hyperthyroidism (486 rulings in all, counting dismissed and withdrawn issues). The Board section on this page breaks these down by remand reason, claim theory and era since 1992; those figures are computed from the data, not typed here.
- Medical sources: PMID 36848916 (hyperthyroidism review: blood-test diagnosis, drug causes, atrial fibrillation as a complication), PMID 40324443 and PMID 27664101 (thyroid eye disease and its course), PMID 32471411 (hypothyroidism after radioactive iodine for Graves' disease).
- Limitations: Pay amounts are VA's 2026 rates for a veteran with no dependents. Board results reflect cases that appealed and are not predictions of individual outcomes, and Claim Raven is data analysis, not legal, medical, or VA-accredited advice.
